Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

Previous post Australia’s central bank shifts to neutral stance on interest rates
Next post LINK rallies by 26% in a week as Uniswap lists AltSignal’s ASI